ReviewChemistryOpen2026
Non-redox Lewis Acids Supported Pd-Catalyzed C-C /C-H Activation and Accession to Produce Pharmaceutical Intermediates.
Review in ChemistryOpen, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Palladium is a simple and versatile redox-active metal that plays a crucial role in the oxidation reactions for organic synthesis and production of pharmaceutical intermediates. Notably, there has been significant progress with Lewis acids (LAs), which are non-redox metal ions promoting Pd(II)-catalyzed oxidation via C-H and C-C bond activation. A new catalytic species is formed through the strong interaction between a Lewis acid and palladium as dimer catalyst. This active complex in this system, which is a Lewis acid promoter, facilitates a Wacker-type oxidation reaction via the activation of C-H and/or C-C bonds. This system of dimer catalysis is based on the key active species for oxidation reactions in pharmaceutical production. The Pd(II)/LA-catalytic oxidation of olefins and N-heteroaromatic alkylation we developed offers a robust method for generating intermediate compounds for drug discovery. This study demonstrates that non-redox Lewis acid-promoted Pd catalysis is highly effective in synthesizing chemically diverse compounds featuring hydrogen-bonding acceptors and donors (HBA/HBD). These functional groups are crucial for interactions with biological targets, making the resulting molecules strong candidates for development as active pharmaceutical ingredients. Their potential applications span pharmaceutical sciences, medicinal delivery systems, and cosmetic formulations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.